ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to inv...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Shane R. Stecklein, Bruce F. Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M. Staley, Qamar J. Khan, Anne P. O’Dea, Lauren E. Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B. Pathak, Andrew K. Godwin, Priyanka Sharma
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Nature Portfolio 2023-03-01
Цуврал:	npj Breast Cancer
Онлайн хандалт:	https://doi.org/10.1038/s41523-023-00512-7
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!